NO20081133L - Tieno[2,3-B]-pyridin-5-karbonitriler som protein kinase inhibitorer - Google Patents

Tieno[2,3-B]-pyridin-5-karbonitriler som protein kinase inhibitorer

Info

Publication number
NO20081133L
NO20081133L NO20081133A NO20081133A NO20081133L NO 20081133 L NO20081133 L NO 20081133L NO 20081133 A NO20081133 A NO 20081133A NO 20081133 A NO20081133 A NO 20081133A NO 20081133 L NO20081133 L NO 20081133L
Authority
NO
Norway
Prior art keywords
tieno
carbonitriles
pyridine
protein kinase
kinase inhibitors
Prior art date
Application number
NO20081133A
Other languages
English (en)
Inventor
Derek Cecil Cole
Magda Asselin
Diane Harris Boschelli
Biqi Wu
Ana Carolina Barrios Sosa
Lawrence Nathan Tumey
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20081133L publication Critical patent/NO20081133L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Forbindelser med formel I: I er beskrevet, hvor R1, R2, R3, R4 og X er definert ovenfor i beskrivelsen, som kan være anvendelige ved behandling av autoimmunsykdommer og inflammatoriske sykdommer, samt fremgangsmåter for fremstilling av disse forbindelsene.
NO20081133A 2005-09-27 2008-03-04 Tieno[2,3-B]-pyridin-5-karbonitriler som protein kinase inhibitorer NO20081133L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72082105P 2005-09-27 2005-09-27
PCT/US2006/037502 WO2007038519A1 (en) 2005-09-27 2006-09-27 Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
NO20081133L true NO20081133L (no) 2008-04-25

Family

ID=37603099

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081133A NO20081133L (no) 2005-09-27 2008-03-04 Tieno[2,3-B]-pyridin-5-karbonitriler som protein kinase inhibitorer

Country Status (16)

Country Link
US (1) US20070082880A1 (no)
EP (1) EP1937690A1 (no)
JP (1) JP2009511439A (no)
KR (1) KR20080059184A (no)
CN (1) CN101273047A (no)
AR (1) AR056200A1 (no)
AU (1) AU2006294726A1 (no)
BR (1) BRPI0616758A2 (no)
CA (1) CA2623228A1 (no)
GT (1) GT200600434A (no)
NO (1) NO20081133L (no)
PE (1) PE20070619A1 (no)
RU (1) RU2008108619A (no)
TW (1) TW200745137A (no)
WO (1) WO2007038519A1 (no)
ZA (1) ZA200802690B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
TW200821318A (en) * 2006-09-26 2008-05-16 Wyeth Corp Process for the preparation of 4-hydroxythieno[2,3-b]pyridine-5-carbonitriles
US20090118276A1 (en) * 2007-11-02 2009-05-07 Wyeth Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
WO2011075559A1 (en) * 2009-12-18 2011-06-23 Glaxo Wellcome Manufacturing Pte Ltd. Novel compounds
EP2611812A1 (en) * 2010-09-01 2013-07-10 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
EP2616441B1 (en) 2010-09-17 2019-08-07 Purdue Pharma L.P. Pyridine compounds and the uses thereof
WO2012136120A1 (zh) * 2011-04-02 2012-10-11 中国人民解放军军事医学科学院毒物药物研究所 芳基丙烯酰胺化合物及其用于制备免疫抑制剂的用途
US9801863B2 (en) 2012-04-16 2017-10-31 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis
WO2015065716A1 (en) 2013-10-15 2015-05-07 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
JP6203820B2 (ja) * 2012-04-16 2017-09-27 ケース ウエスタン リザーブ ユニバーシティ １５−ｐｇｄｈ活性を調節する組成物および方法
KR20240036709A (ko) * 2016-03-11 2024-03-20 에이씨 이뮨 에스에이 진단 및 치료를 위한 바이사이클릭 화합물
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
AU2018215678A1 (en) 2017-02-06 2019-08-22 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity
IL321451A (en) 2018-11-21 2025-08-01 Univ Case Western Reserve Compositions and methods of modulating short-chain dehydrogenase activity
ES2974634T3 (es) 2018-12-21 2024-06-28 Celgene Corp Inhibidores de tienopiridinas de RIPK2
MX2022010258A (es) 2020-02-21 2023-01-24 Univ Case Western Reserve Composiciones y métodos para tratar la lesión renal.
UY39890A (es) * 2021-08-10 2023-03-31 Jacobio Pharmaceuticals Co Ltd Compuestos con diana en mutante de p53
CN114957280B (zh) * 2021-12-31 2024-09-17 成都赜灵生物医药科技有限公司 噻吩[2,3-d]嘧啶衍生物及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA782648B (en) * 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
WO1999024440A1 (en) * 1997-11-11 1999-05-20 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
US5948911A (en) * 1998-11-20 1999-09-07 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to thienopyrimidine derivatives
GB9906566D0 (en) * 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
BR0012157A (pt) * 1999-07-07 2002-04-02 Astrazeneca Uk Ltd Derivado de quinazolina, derivado de pirimidina, processo para a preparação de um derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, método para a prevenção ou tratamento de doenças ou condições médicas pela célula t um em animal de sangue quente em necessidade de tal tratamento
ATE300303T1 (de) * 2000-03-06 2005-08-15 Astrazeneca Ab Verwendung von quinazolinderivate als inhibitoren der angiogenese
AU2001252463A1 (en) * 2000-06-06 2001-12-17 Pfizer Products Inc. Thiophene derivatives useful as anticancer agents
US20020004511A1 (en) * 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
WO2003000194A2 (en) * 2001-06-21 2003-01-03 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
CA2483890C (en) * 2002-06-06 2012-12-11 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
US7674907B2 (en) * 2004-07-23 2010-03-09 Amgen Inc. Furanopyridine derivatives and methods of use
JP2008513463A (ja) * 2004-09-15 2008-05-01 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チアゾロピリジンキナーゼ阻害剤
JP5148499B2 (ja) * 2005-05-20 2013-02-20 メチルジーン インコーポレイテッド Ｖｅｇｆ受容体およびｈｇｆ受容体シグナル伝達の阻害剤

Also Published As

Publication number Publication date
CA2623228A1 (en) 2007-04-05
JP2009511439A (ja) 2009-03-19
CN101273047A (zh) 2008-09-24
KR20080059184A (ko) 2008-06-26
AR056200A1 (es) 2007-09-26
PE20070619A1 (es) 2007-07-02
AU2006294726A1 (en) 2007-04-05
ZA200802690B (en) 2009-08-26
BRPI0616758A2 (pt) 2011-06-28
GT200600434A (es) 2007-05-28
US20070082880A1 (en) 2007-04-12
EP1937690A1 (en) 2008-07-02
RU2008108619A (ru) 2009-11-10
TW200745137A (en) 2007-12-16
WO2007038519A1 (en) 2007-04-05

Similar Documents

Publication Publication Date Title
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
EA200801301A1 (ru) ИНГИБИТОРЫ АКТИВНОСТИ Akt
NO20074666L (no) Imidazo(1,2-A)pyridinforbindelser som VEGF-R2-inhibitorer
GEP20084367B (en) Diazepinoindole derivatives as kinase inhibitors
NO20055496L (no) Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer
WO2007079164A3 (en) Protein kinase inhibitors
NO20092668L (no) 5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl) -pyrimide derivatives useful as protein kinase inhibitors
NO20070731L (no) Heterocykliske forbindelser.
NO20075987L (no) Bisykliske derviater som p38-kinaseinhibitorer
CY1112253T1 (el) Ενωσεις διαμινοτριαζολιου χρησιμες ως αναστολεις κινασης πρωτεϊνης
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
WO2007044084A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
WO2004087699A3 (en) Thiazoles useful as inhibitors of protein kinases
WO2004087698A3 (en) Thiazoles useful as inhibitors of protein kinases
WO2007023110A3 (en) P38 map kinase inhibitors and methods for using the same
GEP20105054B (en) Imidazoquinolines as lipid kinase inhibitors
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
NO20081349L (no) Pyrrolopyrimidinderivater som Syk-inhibitorer
NO20082476L (no) Bicykliske forbindelser med kinaseinhiberende aktivitet
SI1689391T1 (sl) 5-fenil-4-metil-tiazol-2-il-aminski derivati kot inhibitorji fosfatidilinozitol-3-kinaznih encimov (PI3) za zdravljenje vnetnih bolezni dihalnih poti
PL2395004T3 (pl) Pochodne pirolo[2,3-b]pirydyny jako inhibitory kinazy białkowej
DK1812440T3 (da) Pyrazolo[1,5-a]pyrimidiner, der kan anvendes som inhibistorer af proteinkinaser
WO2009006389A3 (en) Pyrimidine derivatives useful as raf kinase inhibitors
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
WO2007095223A3 (en) Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application